Samenvatting
Gezichtsverlies wordt meestal veroorzaakt door refractiestoornissen die eenvoudig met een bril of contactlenzen (of refractieve chirurgie) verholpen kunnen worden. Op latere leeftijd komt cataract in toenemende mate voor. Na chirurgische vervanging van de lens is recuperatie echter de regel. Vasculaire pathologie ter hoogte van de retina of n. opticus is dikwijls oorzaak van blijvend gezichtsverlies, maar kan niet door screening worden voorkomen (behalve diabetische retinopathie). Irreversibel gezichtsverlies ten gevolge van amblyopie, diabetische retinopathie, glaucoom en leeftijdsgebonden maculadegeneratie kan voorkomen worden indien de aandoening op tijd wordt herkend en behandeld.
Literatuur
Pediatric Eye Disease Investigator Group. A randomized trial of atropine vs. patching for treatment of moderate amblyopia in children. Arch Ophthalmol 2002;120:268-78.
Rahi J, Logan S, Timms C, Russell-Eggitt I, Taylor D. Risk, causes and outcomes of visual impairment after loss of vision in the non-amblyopic eye: a population-based study. Lancet 2002;360:597-602.
Tommila V, Tarkkanen A. Incidence of loss of vision in the healthy eye in amblyopia. Br J Ophthalmol 1981;65:575-7.
Eibschitz-Tsimhoni M, Friedman T, Naor J, Eibschitz N, Friedman Z. Early screening for amblyogenic risk factors lowers the prevalence and severity of amblyopia. JAAPOS 2000;4:194-9.
Aiello L. Perspectives on diabetic retinopathy. Am J Ophthalmol 2003;136:122-35.
Patz A, Smith RE. The ETDRS and Diabetes 2000. Ophthalmology 1991;98:739-40.
Kohner EM, Aldington SJ, Stratton IM, et al. United Kingdom Prospective Diabetes Study, 30: diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risk factors. Arch Ophthalmol 1998;116:297-303.
Cavallerano AA, Cavallerano JD, Katalinic P, Tolson AM, Aiello LP, Aiello LM. Use of Joslin Vision Netwerk digital-video non-mydriatic retinale imaging to assess diabetic retinopathy in a clinical program. Retina 2003;23:215-23.
Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Controle and Complication Trial. Diabetes 1995;44:968-83.
The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nefropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000;342:381-89.
UK Prospective Diabetes Study Group. Intensive Blood-glucose controle with sulphonylureas or insuline compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
Ball SG. Benefits of blood pressure reduction in diabetic patients. J Hypertens 2003;21:S31-6.
UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. (UKPDS 38). BMJ 1998;317:703-13.
Chowdhury TA, Hopkins D, Dodson PM, Vafidis GC. The role of serum lipids in exudative diabetic maculopathy: is there a place for lipid lowering therapy? Eye 2002;16:689-93.
van Leiden HA, Dekker JM, Moll AC, Nijpels G, Heine RJ, Bouter LM, et al. Blood pressure, lipids, and obesity are associated with retinopathy: the hoorn study. Diabetes Care 2002;25:1320-5.
Astrup A. Healthy lifestyles in Europe: prevention of obesity and type II diabetes by diet and physical activity. Public Health Nutr 2001;4:499-515.
Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.
Wilensky JT, Kaufman PL, Frohlichstein D, Gieser DK, Kass M, Ritch R, et al. Follow-up of angle-closure glaucoma suspects. Am J Ophthalmol 1993;115:338-36.
Lowe R: Angle-closure glaucoma. The second eye: An analysis of 200 cases. Trans Ophthal Soc Aust 1961;21:65.
Aung T, Ang LP, Chan SP, Chew PT. Acute primary angle-closure: long-term intraocular pressure outcome in Asian eyes. Am J Ophthalmol 2001;131:7-12.
Mackey DA, Craig JE. Predictive DNA testing for glaucoma: reality in 2003. Ophthalmol Clin North Am 2003;16:639-45.
Brandt JD. Corneal thickness in glaucoma screening, diagnosis, and management. Curr Opin Ophthalmol 2004;15:85-89.
Buono LM, Foroozan R, Sergott RC, Savino PJ. Is normal tension glaucoma actually an unrecognized hereditary optic neuropathy? New evidence from genetic analysis. Curr Opin Ophthalmol 2002;13:362-70.
Nouri-Mahdavi K, Hoffman D, Tannenbaum DP, Law SK, Caprioli J. Identifying early glaucoma with optical coherence tomography. Am J Ophthalmol 2004;137:228-35.
Klaver CC, Wolfs RC, Assink JJ, van Duijn CM, Hofman A, de Jong PT. Genetic risk of age-related maculopathy. Population-based familial aggregation study. Arch Ophthalmol 1998;116:1646-51.
van Leeuwen R, Ikram MK, Vingerling JR, Witteman JC, Hofman A, de Jong PT. Blood pressure, atherosclerosis, and the incidence of age-related maculopathy: the Rotterdam Study. Invest Ophthalmol Vis Sci 2003;44:3771-7.
Snellen EL, Verbeek AL, Van Den Hoogen GW, Cruysberg JR, Hoyng CB. Neovascular age-related macular degeneration and its relationship to antioxidant intake. Acta Ophthalmol Scand 2002;80:368-71.
Age-related eye disease study research group. A randomized, placebo-controled, clinical trial of high-dose supplementation with vitamin C and E, beta carotene, and zinc for age related mac ular degeneration and vision loss. AREDS report 8. Arch Ophthalmol 2001;119:1417-36.
van Meurs JC, ter Averst E, Hofland LJ, van Hagen PM, Mooy CM, Baarsma GS, et al. Autologous peripheral retinal pigment epithelium translocation in patients with subfoveal neovascular membranes. Br J Ophthalmol 2004;88:110-3.
Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials (Tap 2). Arch Ophthalmol 2001;119:198-207.
D'Amico DJ, Goldberg MF, Hudson H, Jerdan JA, Krueger S, Luna S, et al. Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD): interim (month 6) analysis of clinical safety and efficacy. Retina 2003;23:14-23.
Eckardt C, Eckardt U, Conrad HG. Macular rotation with and without counter-rotation of the globe in patients with age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 1999;237:313-25.
Mozaffarieh M, Sacu S, Wedrich A. The role of the carotenoids, lutein and zeaxanthin, in protecting against age-related macular degeneration: A review based on controversial evidence. Nutr J 2003;2(1):20.
Seddon JM, Cote J, Rosner B. Progression of age-related macular degeneration: association with dietary fat, transunsaturated fat, nuts, and fish intake. Arch Ophthalmol 2003;121:1728-37.
Author information
Authors and Affiliations
Additional information
oogarts, kliniekhoofd Oogheelkunde van het Universitair Ziekenhuis Antwerpen
Rights and permissions
About this article
Cite this article
Smets, R.M.E. Preventie van verworven irreversibel gezichtsverlies. BIJB 20, 206 (2004). https://doi.org/10.1007/BF03059783
DOI: https://doi.org/10.1007/BF03059783